Effects of different dose of FTY720 on lymphocyte cell cycle arrest in cardiac transplantation model of rats

References

• Adachi, K, Kahora, T, Nakao N, et al. Design,synthesis,and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosupperssan, FTY720. Biol. Med. Chem. Lett. 1995, 5, 853–856.
   Web of Science ®Google Scholar
• Fujita, T., Inoue, K., Yamamoto, S., Ikumoto, T., Sasaki, S., Toyama, R., Chiba, K., Hoshino, Y., Okumoto, T. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J. Antibiot. 1994, 47, 208–215.
   PubMed Web of Science ®Google Scholar
• Wijkstrom, M., Kenyon, N.S., Kirchhof, N., Kenyon, N.M., Mullon, C., Lake, P., Cottens, S., Ricordi, C., Hering, B.J. Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. Transplantation 2004, 77, 827–835.
   PubMed Web of Science ®Google Scholar
• Okazaki, H., Hirata, D., Kamimura, T., Sato, H., Iwamoto, M., Yoshio, T., Masuyama, J., Fujimura, A., Kobayashi, E., Kano, S., Minota, S. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J. Rheumatol. 2002, 29, 707–716.
   PubMed Web of Science ®Google Scholar
• Suzuki, T., Jin, M.B., Shimamura, T., Yamashita, K., Taniguchi, M., Nomura, M., Yokota, R., Fukai, M., Magata, S., Horiuchi, H., Fujita, M., Nagashima, K., Furukawa, H., Todo, S. A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments. Transpl. Int. 2004, 17, 574–584.
   PubMedGoogle Scholar
• Luo, ZJ, Tanaka, T, kimura, F, Miyasaka, M. Analysis of the action of a novel immunosuppressant FTY720 in mice. Immunopharmcology 1999, 41, 199–207.
   PubMedGoogle Scholar
• Shimizu, H., Takahashi, M., Kaneko, T., Murakami, T., Hakamata, Y., Kudou, S., Kishi, T., Fukuchi, K., Iwanami, S., Kuriyama, K., Yasue, T., Enosawa, S., Matsumoto, K., Takeyoshi, I., Morishita, Y., Kobayashi, E. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 2005, 111, 222–229.
   PubMed Web of Science ®Google Scholar
• Furukawa, H., Suzuki, T., Jin, M.B., Yamashita, K., Taniguchi, M., Magata, S., Ishikawa, H., Ogata, K., Masuko, H., Shimamura, T., Fukai, M., Hayashi, T., Fujita, M., Nagashima, K., Omura, T., Kishida, A., Todo, S. Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs. Transplantation 2000, 69, 235–241.
   PubMed Web of Science ®Google Scholar
• Mayer, K., Birnbaum, F., Reinhard, T., Reis, A., Braunstein, S., Claas, F., Sundmacher, R. FTY720 prolongs clear corneal allograft survival with a differential effect on different lymphocyte populations. Br. J. Ophthalmol. 2004, 88, 915–919.
   PubMedGoogle Scholar
• Yan, S., Rodriguez-Barbosa, J.I., Pabst, O., Beckmann, J.H., Brinkmann, V., Förster, R., Hoffmann, M.W. Protection of mouse small bowel allografts by FTY720 and costimulation blockade. Transplantation 2005, 79, 1703–1710.
   PubMedGoogle Scholar
• Cai, J.Q., Tan, J.M., Dong, W.P., Wang, Y.F., Wang, J.B. [Study of the effects of immunosuppressive agents on human islet cells in vitro]. Zhonghua Yi Xue Za Zhi 2005, 85, 654–656.
   PubMedGoogle Scholar
• Kovarik, J.M., Schmouder, R.L., Barilla, D., Büche, M., Rouilly, M., Berthier, S., Wang, Y., Van Saders, C., Mayer, T., Gottlieb, A.B. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. Ann. Pharmacother. 2004, 38, 1153–1158.
   PubMedGoogle Scholar
• Horga, A., Montalban, X. FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Rev. Neurother. 2008, 8, 699–714.
   PubMedGoogle Scholar
• Martini, S., Peters, H., Böhler, T., Budde, K. Current perspectives on FTY720. Expert Opin. Investig. Drugs 2007, 16, 505–518.
   PubMed Web of Science ®Google Scholar
• Kunzendorf, U., Ziegler, E., Kabelitz, D. FTY720–the first compound of a new promising class of immunosuppressive drugs. Nephrol. Dial. Transplant. 2004, 19, 1677–1681.
   PubMed Web of Science ®Google Scholar
• Yopp, A.C., Fu, S., Honig, S.M., Randolph, G.J., Ding, Y., Krieger, N.R., Bromberg, J.S. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J. Immunol. 2004, 173, 855–865.
   PubMedGoogle Scholar
• Li, X.K., Tamura, A., Fujino, M., Guo, L., Kakefuda, T., Funeshima, N., Enosawa, S., Amari, M., Naoe, S., Amemiya, H., Suzuki, S. Induction of lymphocyte apoptosis in rat liver allograft with ongoing rejection by FTY720. Clin. Exp. Immunol. 2001, 123, 331–339.
   PubMedGoogle Scholar
• Li, Q.Y., Chi, Y.Y., Liu, S.Q. Cell cycle arrest effects of large-dose FTY720 on lymphocytes in mouse skin transplantation models. Immunopharmacol. Immunotoxicol. 2008, 30, 365–381.
   PubMed Web of Science ®Google Scholar
• Müller, G., Reiterer, P., Höpken, U.E., Golfier, S., Lipp, M. Role of homeostatic chemokine and sphingosine-1-phosphate receptors in the organization of lymphoid tissue. Ann. N. Y. Acad. Sci. 2003, 987, 107–116.
   PubMedGoogle Scholar
• Fujino, M., Li, X.K., Guo, L., Amano, T., Suzuki, S. Activation of caspases and mitochondria in FTY720-mediated apoptosis in human T cell line Jurkat. Int. Immunopharmacol. 2001, 1, 2011–2021.
   PubMedGoogle Scholar
• Ho, J.W., Man, K., Sun, C.K., Lee, T.K., Poon, R.T., Fan, S.T. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol. Cancer Ther. 2005, 4, 1430–1438.
   PubMedGoogle Scholar
• Tedesco-Silva, H., Szakaly, P., Shoker, A., Sommerer, C., Yoshimura, N., Schena, F.P., Cremer, M., Hmissi, A., Mayer, H., Lang, P.; FTY720 2218 Clinical Study Group. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation 2007, 84, 885–892.
   PubMed Web of Science ®Google Scholar
• Xiong, H.B., Huang, Z.F., Ye, Q.F., Xia, S.S. [Effect of mono and combination therapy with FTY720 and ICAM-1 mAb for mouse-to-rat cardiac xenotransplantation]. Zhong Nan Da Xue Xue Bao. Yi Xue Ban 2007, 32, 41–46.
   PubMedGoogle Scholar
• del Rio M.L., Pabst, O., Ramirez, P., Penuelas-Rivas, G., Förster, R., Rodriguez-Barbosa, J.I. The thymus is required for the ability of FTY720 to prolong skin allograft survival across different histocompatibility MHC barriers. Transpl. Int. 2007, 20, 895–903.
   PubMed Web of Science ®Google Scholar
• Zhao, Y., Man, K., Lo, C.M., Ng, K.T., Li, X.L., Sun, C.K., Lee, T.K., Dai, X.W., Fan, S.T. Attenuation of small-for-size liver graft injury by FTY720: significance of cell-survival Akt signaling pathway. Am. J. Transplant. 2004, 4, 1399–1407.
   PubMedGoogle Scholar
• Brinkmann, V. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br. J. Pharmacol. 2009, 158, 1173–1182.
   PubMed Web of Science ®Google Scholar
• Peng, X., Hassoun, P.M., Sammani, S., McVerry, B.J., Burne, M.J., Rabb, H., Pearse, D., Tuder, R.M., Garcia, J.G. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am. J. Respir. Crit. Care Med. 2004, 169, 1245–1251.
   PubMed Web of Science ®Google Scholar
• Salinas, N.R., Oshima, C.T., Cury, P.M., Cordeiro, J.A., Bueno, V. FTY720 and lung tumor development. Int. Immunopharmacol. 2009, 9, 689–693.
   PubMedGoogle Scholar
• Dragun, D., Fritsche, L., Boehler, T., Peters, H., Budde, K., Neumayer, H.H. FTY720: early clinical experience. Transplant. Proc. 2004, 36, 544S–548S.
   Google Scholar